Ionis Pharmaceuticals Inc (IONS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$58.09-0.07%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IONS
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks IONS against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Drive total revenue growth through commercial launches and partnerships to achieve approximately 20% growth year over year in 2026.
Stated as a priority in 3 of last 3 quarters. Revenue increased from $246 million in 2026-Q1 to $268 million in 2026-Q2, reflecting continued growth. Management's guidance anticipates approximately 20% year-over-year revenue growth in 2026, indicating delivery on this priority.
“On track to achieve 2026 financial guidance including total revenue growth of approximately 20 percent year over year.”
“Overall, the Company anticipates total revenue to grow approximately 20 percent year over year.”
“On track to deliver accelerating value with growth driven by commercial launches and partnerships.”
Grow DAWNZERA product sales to between $110 million and $120 million in 2026 through continued U.S. and international launches.
Stated as a priority in 3 of last 3 quarters. DAWNZERA product sales increased from $16 million in 2026-Q1 to $26 million in 2026-Q2, showing strong growth. Management guidance confirms the $110-120 million sales target for 2026, indicating progress toward this goal.
Execute the launch and commercialization of TRYNGOLZA for severe hypertriglyceridemia following FDA approval in 2026.
Stated as a priority in 3 of last 3 quarters. TRYNGOLZA generated $5 million in net product sales in 2026-Q2 and $32 million in the first half of 2026, demonstrating early launch momentum. Management expects full year 2026 sales of $100-110 million, consistent with their stated launch goals.
Prepare for and execute the launch of zilganersen as the first disease-modifying treatment for Alexander disease, pending FDA approval in 2026.
Stated as a priority in 3 of last 3 quarters. Management confirmed FDA Priority Review with a PDUFA date of September 22, 2026, and ongoing launch preparations. The trajectory is delivering as the company advances toward the planned 2026 launch.
“Zilganersen on track to launch this year as the first and only medicine to demonstrate clinically meaningful benefit in Alexander disease.”
Collaborate with GSK to develop and globally launch bepirovirsen for chronic hepatitis B, with regulatory filings and data presentations in 2026.
Stated as a priority in 2 of last 3 quarters. Management reported positive Phase 3 data and regulatory progress with a PDUFA date of October 26, 2026, supporting plans for a global launch. The trajectory shows progress consistent with stated goals.
“Bepirovirsen on track for global launch this year; positive Phase 3 data presented at EASL 2026.”
Over the trailing year it converted 2.71x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
16 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
“On track to achieve full year 2026 product sales of $110-120 million for DAWNZERA.”
“Generated U.S. net product sales of $16 million in the first quarter of 2026; on track to achieve $110-120 million in 2026.”
“Launch preparations and early sales momentum for DAWNZERA continuing.”
“TRYNGOLZA demonstrating early sHTG launch momentum with $5 million in net product sales in Q2 2026.”
“Olezarsen (TRYNGOLZA) on track to launch this year as a transformational medicine for sHTG.”
“Preparations underway for TRYNGOLZA launch following FDA approval.”
“Zilganersen NDA accepted for Priority Review with PDUFA target action date of September 22, 2026.”
“Launch preparations underway for zilganersen in Alexander disease.”
“Positive Phase 3 B-Well studies data for bepirovirsen; NDA filing accepted with PDUFA date October 26, 2026.”